Preston Klassen - Jan 12, 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
President & Head of R & D, Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Jan 12, 2024
Transactions value $
$0
Form type
4
Date filed
1/17/2024, 05:18 PM
Previous filing
Aug 14, 2023
Next filing
May 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +120K $0.00 120K Jan 12, 2024 Common Stock 120K $1.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.